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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies today with an urgent
need for novel therapeutic strategies. Biomarker analysis helps to better understand tumor biology and might emerge
as a tool to develop personalized therapies. The aim of the study is to investigate four promising biomarkers to predict
the clinical course and particularly the pattern of tumor recurrence after surgical resection.
Design: Patients undergoing surgery for PDAC can be enrolled into the PANCALYZE trial. Biomarker expression of CXCR4,
SMAD4, SOX9 and IFIT3 will be prospectively assessed by immunohistochemistry and verified by rt.-PCR from tumor and
adjacent healthy pancreatic tissue of surgical specimen. Immunohistochemistry expression pattern of all four biomarkers
will be combined into a single score. Beginning with the hospital stay clinical data from enrolled patients will be collected
and followed. Different adjuvant chemotherapy protocols will be used to create subgroups. The combined biomarker
expression score will be correlated with the further clinical course of the patients to test the hypothesis if CXCR4 positive,
SMAD4 negative, SOX9 positive, IFIT3 positive tumors will predominantly develop metastatic spread.
Discussion: Pancreatic cancer is associated with different patterns of progression requiring personalized therapeutic
strategies. Biomarker expression analysis might be a tool to predict the pattern of tumor recurrence and discriminate
patients that develop systemic metastatic disease from those with tumors that rather develop local recurrence over
time. This data might lead to personalized adjuvant treatment decisions as patients with tumors that stay localized
might benefit from adjuvant local therapies like radiochemotherapy as compared to those with systemic recurrence
who would benefit exclusively from chemotherapy.
Moreover, the pattern of propagation might be a predefined characteristic of pancreatic cancer determined by the
genetic signature of the tumor. In the future, biomarker expression analysis could be performed on tumor biopsies to
develop personalized therapeutic pathways right after diagnosis of cancer.
Trial registration: German Clinical Trials Register, DRKS00006179.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer related death in Germany and the
incidence of PDAC increases constantly in most of the
Western countries. Predictions assume that PDAC will be-
come the second leading cause of cancer-related death by
2030 uncovering PDAC to be a serious threat to public
health [1]. The 5-year overall survival rate is around 6%
making PDAC to one of the most lethal cancers of all
known malignancies. Surgical resection remains the only
potential curative treatment for PDAC raising the 5-year
survival rate up to 14%. However, at the time of diagnosis
less than 20% of the tumors are resectable while most are
locally advanced or metastasized and thus inoperable.
The reasons for the late time of diagnosis are lack of
specific symptoms in the early stage, nonspecific and
varying symptoms in the advanced stage as well as rap-
idly aggressive tumor growth with a high tendency for
metastatic spread. Today, postoperative adjuvant chemo-
therapy (CTx) based on gemcitabine or 5-fluorouracile is
standard care of treatment for resected patients. How-
ever, despite adjuvant therapy almost 80% of all patients
suffer from tumor recurrence within 2 years after resec-
tion. With a probability of 20% to 30% tumor recurrence
is locally restricted whereas in the majority of patients
the tumor systemically spreads to distant sites like liver
and peritoneum [2, 3].
According to current clinical guidelines, patients with lo-
cally advanced, unresectable non-metastatic pancreatic can-
cer (LAPC) can receive intensified induction chemotherapy/
radiochemotherapy to eventually achieve resectability. This
induction therapy selects patients into two groups over time:
some tumors stay localized and surgery may be attempted.
All other tumors develop chemoresistance and subsequently
metastatic disease. Induction therapy might influence tumor
biology as tumors can acquire additional pathogenic muta-
tions and epigenetic changes under chemotherapy/radioche-
motherapy. However, Krishnan et al. found 50% of 247
patients with LAPC developing metastatic disease under in-
duction radiochemotherapy and 45% of 76 patients under
sequential chemotherapy followed by chemoradiotherapy
[4]. This observation suggests that the type of induction
therapy might not fundamentally influence the type of
tumor dissemination and that the type of tumor dissemin-
ation (metastatic disease versus localized disease) might be a
principal characteristic of pancreatic cancer determined by
the initial genetic signature of the tumor. If this basic char-
acteristic could be assessed with biomarker expression
analysis at the time of diagnosis tumor treatment could be
optimized individually in the future.
After resection, patients with tumors that stay local-
ized over time might benefit from additional local ther-
apies, like adjuvant radiochemotherapy. Patients at risk
for developing early metastatic disease might not benefit
from surgery at all. To develop individualized therapies
for PDAC patients it is necessary to anticipate the clin-
ical course of the disease. With specific biomarkers or a
panel of biomarkers it might be possible to predict the
pattern of recurrence and distinguish patients who will
develop locally restricted disease from those who will
suffer from distant metastatic spread. Studies already
have been carried out to identify single biomarkers pre-
dicting the clinical course of PDAC but none were suffi-
cient to infer treatment schemes for individual patients
(for a systematic review, see [5]). Bachet et al. found
high CXCR4 expression to be significantly associated
with distant recurrence but the sensitivity and specificity
of high CXCR4 expression to predict metastatic disease
was 55% and 63%, respectively [6]. In this study we will
prospectively analyze a panel of 4 biomarkers to predict
the clinical course of PDAC after surgical resection. We
hypothesize that a combination of biomarkers is super-
ior to a single biomarker in anticipating the individual
clinical course. We aim to identify patients who develop
metastatic disease with a score derived from biomarker
expression analysis. To do so we will analyze tumor
samples from pancreatic resections and correlate the
combined immunohistochemistry score with the clinical
course to test our hypothesis. The 4 biomarkers might
help to personalize treatment regimens in the future,
thereby extending survival and reducing side effects of
pancreatic cancer treatment.
Design
In this study (see Table 1) we will analyze 4 biomarkers,
two established proteins -CXCR4 and SMAD4- that are
believed to be related to PDAC outcome and two new
biomarkers derived from our own basic research -SOX9
and IFIT3- that were already studied in a small group of
patients. We will test the hypothesis that patients with
CXCR4+SMAD4−SOX9+IFIT3+ primary PDAC will pre-
sumably develop metastatic disease. To that end patients
with primary PDAC undergoing surgical resection will
be included. Likewise patients with locally advanced tu-
mors after receiving neoadjuvant treatment regimens to
downsize the tumor can enter this study when tumor
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resection is performed. Participation in other studies is
not an exclusion criterion and patients may enter add-
itional chemotherapy studies that do not interfere with
our biomarker analysis.
To receive a homogenous patient population we
will conduct a multicenter study with a planned
short recruitment period. This approach ensures that
the patients receive similar postoperative adjuvant
treatment protocols and allows a longer follow-up. It
is planned to recruit around 410 patients in 14 study
centers located in 6 different German states within
3 years.
Patients will be admitted to one of the participating
centers and evaluated for study inclusion. If PDAC is
suspected and curative surgery is intended the patient
can enroll into this study after giving informed con-
sent to the surgeon. Surgery will be performed with
no specific requirements from the study protocol ac-
cording to the German S3-guidelines for PDAC [7].
During surgery peripheral blood will be taken and
stored in the biobank to answer possible future scien-
tific questions. After successful resection the patholo-
gist will prepare paraffin embedded tumor samples
and samples of adjacent pancreatic tissue from the
surgical specimen and send them to the University
Hospital Cologne establishing a central biobank. If
possible, additional tumor samples will be collected
and embedded in RNA stabilization reagent for
Table 1 World Health Organization Trial Registration Data Set describing the PANCALYZE study
Data category Information
Primary registry and trial identifying number German Clinical Trials Register (DRKS)
http://drks-neu.uniklinik-freiburg.de/drks_web/ DRKS00006179
Date of registration in primary registry 2014/05/20
Secondary identifying numbers -
Source(s) of monetary or material support Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
Clinic for General, Visceral and Vascular Surgery, University Clinic Magdeburg, Germany
Celgene GmbH, Joseph-Wild-Straße 20, 81,829 München
Primary sponsor Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
Kerpener Str. 62, 50,937 Köln
Secondary sponsor(s) -
Contact for public queries Dr. Felix Popp
Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
Kerpener Str. 62, 50,937 Köln
pancalyze@uk-koeln.de
Contact for scientific queries Dr. Felix Popp
Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
Kerpener Str. 62, 50,937 Köln
pancalyze@uk-koeln.de
Public title Evaluation of molecular markers to predict the pattern of tumor recurrence and prognosis
in pancreatric ductal adenocarcinoma
Scientific title A multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and
IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence
of the disease
Countries of recruitment Germany
Health condition(s) or problem(s) studied C25 - Malignant neoplasm of pancreas
Intervention(s) none
Key inclusion and exclusion criteria inclusion criteria: patients with primary PDAC undergoing surgical resection
exclusion criteria: Patient is inoperable, No tumor samples can be taken, no ductal
adenocarcinoma or intraductal papillary mucinous neoplasm (IPMN) in the final histology
Study type Non-interventional observation
Date of first enrolment May 2014
Target sample size 450
Recruitment status Recruiting
Primary outcome(s) Correlation of biomarker expression and clinical course
Key secondary outcomes none
Version 2014/05/20 Original Version 1.0
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quantification of mRNA expression. However, the col-
lection of paraffin embedded samples alone is suffi-
cient to participate in the study. Tissue samples are
collected strictly after TNM staging and patients with
no leftover tumor tissue thereafter have to be excluded
from the study. Likewise, patients with other final histo-
logical findings than PDAC cannot proceed within the
study protocol. If the margins of the resected specimen
show tumor cells when analyzed under the microscope
(R1 resection), the patient can stay in the study as this
population might still benefit from surgery and additional
biomarker driven therapy in the future.
Immunohistochemistry will be prospectively performed to
assess biomarker expression of the tumors. This biomarker
analysis will be correlated with the pattern of recurrence of
the corresponding patients. The requisite clinical data will
be collected over a 2-year follow-up observation period
every 6 month by the coordinating center (see Table 2).
Thus, it is possible to follow the individual patient’s clinical
course and test if patients with CXCR4+SMAD4−SOX9
+IFIT3+ tumors will develop metastatic spread (see Fig. 1).
Ethical approval was obtained from the ethics com-
mittee of the University Hospital Cologne. Ethical ap-
proval was also obtained from the regional medical
board’s ethics committees of the following German
federal states: Sachsen-Anhalt, Sachsen, Brandenburg,
Baden-Württemberg, Niedersachsen, Mecklenburg-
Vorpommern. The study is registered at the German
Clinical Trials Register (DRKS00006179, see Table 1).
Biomarkers of the PANCALYZE study
CXCR4
C-X-C chemokine receptor type 4 (CXCR4) is a trans-
membrane G-protein-coupled receptor which is expressed
on cells of the immune system and on cancer cells. In
contrast to other members of its family CXCR4 is
activated by a single known ligand: CXCL12 which is
also known as stromal-derived factor-1 (SDF-1).
CXCL12 is highly expressed in lymph nodes, lung,
liver and bone marrow and the CXCR4-CXCL12 axis
plays an important role for stem cell homing to the
bone marrow and the migration of leukocytes via
chemotaxis - the directional migration of cells toward
the higher concentration of the chemokine. Anti-
CXCR4 blocking antibodies are explored to mobilize
hematopoietic stem cells for bone marrow transplant-
ation [8]. Acquirement of migratory functionality
might play an important role in the development of
metastasis: high expression of CXCR4 on cancer cells
might induce their migration to tissue with high
levels of CXCL12 [9]. CXCR4 expression has also
been linked to over 20 different types of cancer like
breast cancer [10], colon cancer [11], prostate cancer
[12] and melanoma [13] demonstrating that the
CXCR4/CXCL12-axis is involved in tumor progres-
sion, angiogenesis, metastasis and survival. In vitro
and in vivo studies also have shown a correlation be-
tween tumor metastasis and alterations in CXCR4/
CXCL12 signaling in PDAC [7, 12–16]. In a
Table 2 Schedule of enrolment, interventions and assessments (the responsible person is stated in brackets). As resectability of the tumor
is a prerequisite to obtain tissue samples, the day of surgery (day 0) is the time point of allocation. Day of discharge (dis). Month (m)
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out












Take 15 ml blood sample
(surgeon)
X





Demographic data, operation procedure,
complications
X
Recurrence pattern, survival time, adjuvant tumor
therapy and hospital admissions
X X X X
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monocentric study high CXCR4 expression has found
to be an independent prognostic biomarker in PDAC
[17]. In the largest retrospective clinical study investi-
gating CXCR4 including a total of 471 patients Bachet
et al. described high CXCR4 expression to be a strong
negative prognostic biomarker and predictor for the
development of metastatic spread [6].
SMAD4
The SMAD4 protein is a central mediator of the
transforming-growth-factor β (TGF-β) signaling pathway.
The TGF-β-family members regulate cell proliferation, dif-
ferentiation and migration during embryonic development
and tissue homeostasis in the adult. Aberrations in the sig-
naling pathways have been linked to various diseases, such
as autoimmune diseases, cardiovascular diseases and can-
cer. At autopsy Iacobuzio-Donahue et al. found loss of
SMAD4 expression in only 22% of locally advanced car-
cinomas (n = 9) in contrast to 78% of patients with wide-
spread metastatic disease (n = 22) [3]. Crane et al. showed
in a phase II trial for locally advanced (T4) PDAC that 11
of 15 patients (73,3%) with intact SMAD4 expression suf-
fered from local recurrence, and 10 of 14 Patients (71,4%)
with loss of SMAD4 expression developed distant relapse
[18]. However, there is diverging data concerning loss of
SMAD4 expression as a predictor of survival and as a bio-
marker to predict the pattern of recurrence [3, 18]. In a
multicenter study with 471 patients who underwent sur-
gery for PDAC, SMAD4 evaluation did not correlate with
recurrence pattern but hints on a survival benefit for adju-
vant CTx [6]. Still, the huge amount of available data
prompted us to include SMAD4 in the PANCALYZE trial,
not least to resolve existing discrepancies.
SOX9
SRY (sex determining region Y)-box 9 (SOX9) is a mem-
ber of a high conserved family of transcription factors de-
fined by their similarity to the “high mobility group”
structure of the DNA binding domain. SOX9 plays an im-
portant role in sex determination, in chondrogenesis and
in differentiation of multiple organs including normal
pancreatic tissue [19]. Several studies have shown that
SOX9 is differently expressed in many types of cancer,
such as urothelial cancer [20], prostate cancer [21] and
lung cancer [22] and is associated with tumor initiation
and progression. Recently, Tanaka et al. investigated SOX9
expression in PDACs and in intraductal papillary mucin-
ous neoplasms (IPMN). They found the rate of SOX9
positive cells was 82,7% in normal pancreatic tissue and
0,8% in PDAC. In IPMNs the rate of SOX9 positive cells
decreased continuously with tumor progression [23]. In
contrast to these findings recent studies demonstrated
SOX9 overexpression in PDAC [24–27]. Kopp et al. iden-
tified SOX9 to be a critical mediator of acinar-to-ductal
cell transformation which in turn is a principal mechan-
ism of PDAC initiation [24]. SOX9 expression is associ-
ated with an unfavorable prognosis [28]. We have shown
that inhibition of SOX9 expression in an orthotropic
mouse PDAC tumor model leads to significant tumor size
reduction, less angiogenesis, and fewer metastases [27].
Taken together SOX9 is a promising novel marker to be
included into the PANCALYZE trial.
IFIT3
Interferon-induced protein with tetratricopeptide repeats
3 (IFIT3) is one of numerous Interferon (IFN) stimulated
genes (ISGs). Four canonical IFIT family members have
been identified in humans- IFIT1, IFIT2, IFIT3 and IFIT5-
that play important roles as effector molecules of the in-
nate immune system. IFITs reside in the cytoplasm of host
cells and can directly recognize viral specific RNA signa-
ture molecules [29]. Thereby they can inhibit distinct
steps in the translation of viral RNA [30]. The role of
IFIT3 in cancer is not well understood but inflammation
is linked to pancreatic cancer progression and treatment-
resistant metastasis. We have found that overexpression
of IFIT3 enhances tumor growth, angiogenesis, metastasis
and chemoresistance in vitro and therefore IFIT3 seems
to be a tumor promoting protein. Moreover, IFIT3 over-
expression was associated with poor prognosis in an ex-
plorative tissue microarray analysis of 250 human PDAC
samples (unpublished observation). To complement these
interesting data we included IFIT3 into our study analysis.
Fig. 1 Design of the PANCALYZE trial: Tumor tissue samples are collected during surgery. Biomarker expression of CXCR4, SMAD4, SOX9 and IFIT3 will
be assessed using immunohistochemistry. The patients are followed up to analyze if CXCR4+SMAD4−SOX9+IFIT3+ tumors will develop metastatic spread
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Tissue sample analysis
Biomarker expression will be evaluated semi-quantitatively
using standard immunochemistry. CXCR4 expression will
be classified on a scale from 0 to 3, SMAD4 from 0 to 1,
SOX9 from 0 to 2 and IFIT3 from 0 to 1. Samples will be
examined by observers that are blinded to both clinicopath-
ological data and the clinical course of the patients. Intra-
observer and inter-observer variability will be controlled by
multiple evaluations of the same sample by a single obser-
ver and by two independent trained observers evaluating
the same sample, respectively. The grading of all four bio-
markers will be combined into a single score (the
PANCALYZE-score) as follows:
PANCALYZE-score = CXCR4 + 3*(1-SMAD4) + 3/2*
SOX9 + 3*IFIT3.
Thus the PANCALYZE-score can be a number be-
tween 0 and 12 and represents the combined biomarker
expression analysis. The PANCALYZE-score is modelled
to normalize the semi-quantitative biomarker analysis.
The weight factors ensure that all 4 biomarkers contrib-
ute to the PANCALYZE-score equally. The factors can
be adjusted if one biomarker turns out to be significantly
stronger compared to the others.
We expect to collect fewer samples for quantification of
RNA expression fixed in RNAlater® because of the higher
technical complexity to freeze and store these samples at
the participating centers. These samples are used to confirm
immunohistochemistry analysis using reverse transcription
quantitative polymerase chain reaction (RT-qPCR) as a sec-
ond method to analyze CXCR4, SMAD4, SOX9 and IFIT3
mRNA expression of the tumor.
Data management
Documentation of demographic data, the operation pro-
cedure and complications during the hospital stay is ac-
complished by the surgeon of the participating center
until the day of discharge. Follow-up assessing recurrence
pattern, survival time, adjuvant tumor therapy and hos-
pital admissions is performed by telephone interview with
the attending oncologist by the coordinating center (see
Table 2). Patients have to give informed consent as per-
sonal patient data must be stored non-encrypted to con-
duct follow-up. For analysis personal data will be
pseudonymized. To collect data with minimal training of
participating study centers we developed electronic forms
for hospital data assessment as well as follow-up data as-
sessment in portable document format (PDF, forms in
German can be requested from the contact for scientific
queries). PDF forms are user-friendly to handle and re-
quire no additional IT-infrastructure to be implemented
in participating centers. They can be distributed conveni-
ently to participating hospitals and sent back securely to
the coordinating center (University Hospital Cologne).
Data will be extracted from PDF files and stored in a
central data base (MySQL, Oracle, Redwood City) in Co-
logne. This data base is managed by the institute for Qual-
ity Control in Operative Medicine which also monitors
data quality independently from the sponsor. The final
dataset can be accessed by the authors. Other researchers
can apply for tissue samples and the dataset. The steering
committee decides on a case by case basis if this scientific
request is accepted.
Statistical analysis and sample size calculation
The following variables will be collected for each patient:
patient demographics, CA19-9, CEA, tumor characteristics
(size, stage, grade, pathologic margin status, lymph node
metastasis, lymphovascular invasion and perineural inva-
sion). One-way ANOVA analysis will be used to identify
new and published risk factors for metastatic spread and
local recurrence [31]. To address the influence of adjuvant
chemotherapy several subgroups will be defined: gemcita-
bine alone, gemcitabine and nab-paclitaxel, 5-fluorouracil
based and others. As chemo- and radiotherapy might in-
fluence biomarker expression, we will analyze patients
with locally advanced tumors receiving neoadjuvant ther-
apy separately.
The PANCALYZE trail aims to develop a test to iden-
tify patients that develop metastatic spread and dis-
criminate them from the other patients. Thus the
PANCALYZE-score is a binary classifier. As no other
test exists today we will conduct a phase I study. The
receiver operating characteristic (ROC curve) is a well-
established method to describe the performance of such
a test. As the PANCALYZE-score is ordinal, ROC
curves can be applied. To that end the PANCALYZE-
score must be compared with the gold standard, the
best possible method to identify patients with meta-
static spread. Because the median survival of all pa-
tients is 21 months and we will follow the clinical
course for at least 2 years it will be possible to exactly
determine the pattern of recurrence of almost all pa-
tients. Thus ROC curve analysis will allow elucidating
the performance of the PANCALYZE-score. Statistical
analysis will be performed using the R environment for
statistical computing (http://www.r-project.org/) and
the package pROC [32].
Because this study is a phase I study there is no other
test to compare the PANCALYZE-score to. Therefore the
area under the ROC curve (AUC) serves as a parameter to
qualify the test. To determine if the PANCALYZE-score
can successfully discriminate patients with metastatic
spread from the remaining patients the AUC must exceed
0.5. For the patient a far-reaching decision to conduct a
non-standard therapy might rely on the quality of the test
in the future. Therefore one would expect a better accur-
acy of the test demanding that the AUC exceeds 0.6.
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Assuming a significance level of 0.05 and a power of 0.95
a total of 410 patients have to be included into the study
[33]. Secondary objectives are overall and disease free sur-
vival time which is measured from the date of surgery to
the date of death.
Discussion
The PANCALYZE trail aims to predict the clinical course
of pancreatic cancer on the basis of CXCR4, SMAD4,
SOX9 and IFIT3 expression. The biomarker analysis will
be performed immediately after surgery to prospectively
verify the hypothesis that patients with CXCR4+SMAD4
−SOX9+IFIT3+ tumors most likely will develop metastatic
spread.
The idea behind the PANCALYZE trail is that the pattern
of propagation of pancreatic cancer is predefined by the
genetic signature of the tumor. This hypothesis is strength-
ened by data from Iacobuzio-Donahue et al. [3] who ob-
served 30% of patients with localized tumors versus 70%
with metastatic disease at autopsy independent of the clin-
ical stage at initial presentation. Today sophisticated tools
like gene sequencing and DNA microarrays exist to analyze
genetic signatures of tumors. However, these techniques re-
quire immense technical and financial efforts, which cannot
be met in clinical daily routine and are limited to clinical
trials today. With the help of cleverly selected biomarkers
analyzed by immunohistochemistry the essential genetic
signature defining tumor propagation might still be assess-
able. Immunohistochemistry can be performed in any hos-
pital and might therefore be a valuable tool to predict the
pattern of progression. However, immunochemistry is sub-
ject to the interpretation of the observer and interobserver
error must be addressed in future studies.
We believe that one biomarker is not sufficient to en-
compass the complex mechanisms controlling tumor
spread. Encouraging data from Bachet et al. [6] under-
mines the importance of CXCR4 expression for predicting
disease prognosis and pattern of recurrence. However,
CXCR4 as a single marker predicts the occurrence of
metastatic spread with a sensitivity of 55% and a specificity
of 63%. To deviate from current guidelines and give a pa-
tient a personalized different treatment according to bio-
marker analysis a more precise test is required. The
combination of the 4 biomarkers is more robust and might
be able to reliably predict the pattern of propagation.
The PANCALYZE study is a platform to test novel bio-
markers. Additional biomarkers are evaluated constantly. If
they have the potential to predict the pattern of recurrence
they might be incorporated into the PANCALYZE-score.
Promising biomarkers are best selected using genome wide
transcriptome studies. Statistical analysis can reveal a few
signature biomarkers describing the complex tumor biol-
ogy. These are analyzed in the PANCALYZE-study using
immunohistochemistry.
Fig. 2 Future perspective: Today every patient receives adjuvant chemotherapy after surgical resection, regardless of individual tumor characteristics
(a). If it is possible to predict the pattern of failure reliably, tumor treatment can be individualized and linked to biomarker expression patterns. Patients
most likely developing metastatic spread might need intensified chemotherapy. Patients developing local recurrence might benefit from localized
therapies like radiochemotherapy (b)
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If our hypothesis is confirmed, future tumor treatment
can be linked to biomarker expression patterns. Patients
that most likely will experience metastatic spread after
surgery might require intensified adjuvant CTx. Patients
with localized disease that stays localized might benefit
from additional local adjuvant treatment regimens like ra-
diochemotherapy (see Fig. 2). If the basic pattern of propa-
gation is predetermined by the biology of the tumor,
surgery, CTx and radiochemotherapy most likely won’t
change the pattern of failure fundamentally. In the future
biomarker analysis can be extended and performed on
tumor biopsies. Patients with a biomarker expression pat-
tern indicating a high risk of developing metastases might
not benefit from surgery at all. Biomarker analysis on bi-
opsies may be used to identify personalized neoadjuvant
therapies. Patients with a biomarker expression pattern as-
sociated with tumors that stay localized might benefit
from neodjuvant radiochemotherapy even if the primary
tumor is resectable.
In conclusion, biomarker analysis of a large quantity of
pancreatic cancers as envisioned in the PANCALYZE
trail will contribute to develop individualized treatment
options in the future. Predicting the pattern of recur-
rence with the help of biomarkers is the first step toward
personalized medicine for pancreatic cancer patients.
Trail status
To recruit the 450 patients in short time, 14 hospitals
from 6 different German states agreed to join the PAN-
CALYZE trail. The study protocol was approved by the
ethic committees of the University Hospital Cologne and
of medical board’s ethics committees of 6 German federal
states. Today, 14 hospitals already started to recruit pa-
tients. The current list of participants can be obtained by
the primary sponsor (use contact for scientific queries). By
the time of submission 39 patients were included into the
study. The recruitment is planned to be completed until
2019. The follow-up will be performed until 2021.
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